#151560

AhCre Mouse

Cat. #151560

AhCre Mouse

Cat. #: 151560

Sub-type: Mouse

Availability: 6-8 weeks

Disease: Intestinal cancer

Model: Conditional KO

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Douglas Winton

Institute: Cancer Research UK, Cambridge Institute

Tool Details
Handling
Target Details
References

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: AhCre Mouse
  • Research fields: Cancer;Genetics;Metabolism
  • Tool sub type: Mouse
  • Disease: Intestinal cancer
  • Model: Conditional KO
  • Conditional: Yes
  • Conditional description: Inducible Cre expression upon treatment with lipophilic xenobiotic (beta-napthoflavone) enabling inducible expression of Cre recombinase at site of administration (ingestion enables gut-specific Cre expression, injection enables injection-site-specific Cre expression.
  • Description: Cre under CYP1A1 promoter enabling inducible recombinase expression with administration of lipophilic xenobiotic (tissue-specific loxP knockout/knockin/transgene) Cre expressed under CYP1A1 promoter, inducible recombinase expression, conditional to site of injection of inducing chemical.
  • Genetic background: An AhCre transgene vector, containing the cre coding sequence under the rat CYP1A1 promoter, was injected into fertilized CBAxC57BL6 oocytes. Founder mice were backcrossed onto C57BL6 mice to establish transgenic lines. Heterozygous transgenic lines were interbred to establish homozygous AhCre mice.
  • Phenotype: The AhCre mouse exhibits sensitive, controllable Cre recombinase induction and activity upon administration of lipophylic xenobiotics (i.e. beta-napthoflavone, betaNP). The AhCre mouse is particularly useful for knockin/knockout/transgene studies of loxP flanked genes in crypt and villus epithelia of the small intestine, with Cre induction levels regulatable by dose, administration route, or timecourse.Non-induced AhCre mice demonstrate no Cre expression, while induced AhCre mice demonstrate nuclear Cre staining in tissues (widespread staining in small intestine crypts and villi; sporadic staining in liver, pancreas and esophageal epithelia) and succesful recombination of loxP sites. The timecourse of administration and the dose of betaNP can be altered to induce varying levels of Cre induction (and therefore varying levels of recombination/traget gene effect). In addition, the mode of administration (IP versus oral feeding) can also be used to alter the Cre expression pattern; IP inducing SI crypt epithelial Cre expression, oral inducing villus epithelial Cre expression.The AhCre mouse presents researchers with an ideal tool for the controlled study of gene function and genetic alteration in the GI tract.Method; intraperitoneal injection of 80mg/kg beta-napthoflavone (bNP) dissolved in corn oil (8mg/mL) OR oral feeding of bNP in corn oil (8mg/mL) mixed with standard rodent food.
  • Zygosity: Homozygous
  • Production details: An AhCre transgene vector, containing the cre coding sequence under the rat CYP1A1 promoter, was injected into fertilized CBAxC57BL6 oocytes. Founder mice were backcrossed onto C57BL6 mice to establish transgenic lines. Heterozygous transgenic lines were interbred to establish homozygous AhCre mice.
  • Additional notes: The AhCre mouse exhibits sensitive, controllable Cre recombinase induction and activity upon administration of lipophylic xenobiotics (i.e. beta-napthoflavone, betaNP). The AhCre mouse is particularly useful for knockin/knockout/transgene studies of loxP flanked genes in crypt and villus epithelia of the small intestine, with Cre induction levels regulatable by dose, administration route, or timecourse.Non-induced AhCre mice demonstrate no Cre expression, while induced AhCre mice demonstrate nuclear Cre staining in tissues (widespread staining in small intestine crypts and villi; sporadic staining in liver, pancreas and esophageal epithelia) and succesful recombination of loxP sites. The timecourse of administration and the dose of betaNP can be altered to induce varying levels of Cre induction (and therefore varying levels of recombination/traget gene effect). In addition, the mode of administration (IP versus oral feeding) can also be used to alter the Cre expression pattern; IP inducing SI crypt epithelial Cre expression, oral inducing villus epithelial Cre expression.The AhCre mouse presents researchers with an ideal tool for the controlled study of gene function and genetic alteration in the GI tract.Method; intraperitoneal injection of 80mg/kg beta-napthoflavone (bNP) dissolved in corn oil (8mg/mL) OR oral feeding of bNP in corn oil (8mg/mL) mixed with standard rodent food.

Handling

  • Shipping conditions: Embryo/Spermatoza- Dry Ice

Target Details

  • Target: Cre recombinase under the CYP1A1 promoter.

References

  • Stringer et al. 2012. Development. 139(3):465-74. PMID: 22190642.
  • Cdx2 determines the fate of postnatal intestinal endoderm.
  • Kemp et al. 2004. Nucleic Acids Res. 32(11):e92. PMID: 15247325.
  • Elimination of background recombination: somatic induction of Cre by combined transcriptional regulation and hormone binding affinity.
  • Ireland et al. 2004. Gastroenterology. 126(5):1236-46. PMID: 15131783.
  • Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin.